Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
Intelligent Bio Solutions (Nasdaq: INBS) has partnered with B2i Digital to launch an investor-focused marketing campaign. The initiative aims to raise awareness of INBS' patented drug screening technology, which provides a non-invasive alternative to traditional drug tests. B2i Digital will implement digital marketing strategies to highlight the company's Intelligent Fingerprinting Drug Screening System, which is expected to enter the U.S. market in 2025 following FDA 510(k) submission and anticipated clearance. The campaign will focus on reaching healthcare technology investors and emphasize INBS' growing revenue and planned market expansion.
Intelligent Bio Solutions (Nasdaq: INBS) ha collaborato con B2i Digital per lanciare una campagna di marketing rivolta agli investitori. L'iniziativa mira ad aumentare la consapevolezza della tecnologia brevettata di screening dei farmaci di INBS, che offre un'alternativa non invasiva ai test tradizionali per le sostanze stupefacenti. B2i Digital attuerà strategie di marketing digitale per mettere in evidenza il Sistema di Screening dei Farmaci con Impronte Intelligenti dell'azienda, che si prevede entrerà nel mercato statunitense nel 2025 dopo la presentazione della documentazione FDA 510(k) e la prevista approvazione. La campagna si concentrerà sul raggiungimento degli investitori in tecnologie sanitarie e sottolineerà la crescita delle entrate di INBS e l'espansione pianificata del mercato.
Intelligent Bio Solutions (Nasdaq: INBS) se ha asociado con B2i Digital para lanzar una campaña de marketing enfocada en inversores. La iniciativa tiene como objetivo aumentar la concienciación sobre la tecnología patentada de detección de drogas de INBS, que proporciona una alternativa no invasiva a las pruebas tradicionales de drogas. B2i Digital implementará estrategias de marketing digital para destacar el Sistema de Detección de Drogas con Huellas Inteligentes de la empresa, que se espera que ingrese al mercado estadounidense en 2025 tras la presentación de la documentación FDA 510(k) y la aprobación anticipada. La campaña se centrará en alcanzar a los inversores en tecnología sanitaria y enfatizará el crecimiento de los ingresos de INBS y la expansión planificada del mercado.
Intelligent Bio Solutions (Nasdaq: INBS)는 B2i Digital과 협력하여 투자자 중심의 마케팅 캠페인을 시작했습니다. 이 이니셔티브는 INBS의 특허받은 약물 검사 기술에 대한 인식을 높이는 것을 목표로 하며, 이는 전통적인 약물 검사에 대한 비침습적인 대안을 제공합니다. B2i Digital은 회사의 지능형 지문 약물 검사 시스템을 강조하기 위해 디지털 마케팅 전략을 구현할 것이며, 이 시스템은 FDA 510(k) 제출 및 예상 승인을 통해 2025년에 미국 시장에 진입할 것으로 기대됩니다. 이번 캠페인은 의료 기술 투자자에게 도달하는 데 중점을 두며 INBS의 증가하는 수익 및 계획된 시장 확장을 강조할 것입니다.
Intelligent Bio Solutions (Nasdaq: INBS) s'est associé à B2i Digital pour lancer une campagne de marketing axée sur les investisseurs. L'initiative vise à sensibiliser le public à la technologie de dépistage de drogue brevetée d'INBS, qui offre une alternative non invasive aux tests de drogue traditionnels. B2i Digital mettra en œuvre des stratégies de marketing numérique pour mettre en avant le Système de Dépistage de Drogues par Empreintes Intelligentes de l’entreprise, qui devrait entrer sur le marché américain en 2025 après la soumission à la FDA 510(k) et l'approbation attendue. La campagne se concentrera sur l'atteinte des investisseurs en technologie de la santé et soulignera l'augmentation des revenus d'INBS et l'expansion prévue sur le marché.
Intelligent Bio Solutions (Nasdaq: INBS) hat sich mit B2i Digital zusammengeschlossen, um eine investorengerechte Marketingkampagne zu starten. Ziel der Initiative ist es, das Bewusstsein für die patentierte Droge-Screening-Technologie von INBS zu erhöhen, die eine nicht-invasive Alternative zu traditionellen Drogentests bietet. B2i Digital wird digitale Marketingstrategien umsetzen, um das Intelligente Fingerabdruck-Drogen-Screening-System des Unternehmens hervorzuheben, das voraussichtlich 2025 nach der Einreichung der FDA 510(k)-Dokumentation und der erwarteten Genehmigung auf den US-Markt eintreten wird. Die Kampagne wird sich darauf konzentrieren, Investoren im Gesundheitswesen zu erreichen und das wachsende Einkommen von INBS sowie die geplante Markterweiterung zu betonen.
- Planned expansion into U.S. market in 2025
- Growing revenue reported
- FDA 510(k) submission in progress
- None.
Insights
This news release about a marketing partnership with B2i Digital represents a routine corporate communication effort that does not materially impact INBS's financial position or operations. While the partnership aims to increase investor awareness, it's primarily a standard PR initiative without immediate financial implications. The mention of future FDA submission and market entry in 2025 remains speculative without concrete timelines or regulatory milestones. For a micro-cap company with
Digital Marketing Initiatives to Highlight Innovative Non-Invasive Drug Screening Technology and Market Expansion Plans
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS’ patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.
“Intelligent Bio Solutions has developed a groundbreaking system that addresses a critical need in industries requiring quick and reliable drug screening,” said David Shapiro, CEO of B2i Digital. “The company’s Intelligent Fingerprinting Drug Screening System, expected to enter the U.S. market next year following the company’s FDA 510(k) submission and anticipated clearance, provides substantial advantages over traditional methods and offers significant growth potential. We are proud to raise awareness of a company whose products address a critical need across industries worldwide.”
B2i Digital will leverage data-driven targeting across digital channels to reach investors with a focus on healthcare technology and market innovation. The partnership will emphasize Intelligent Bio Solutions’ unique technology, growing revenue, and planned US product launch in 2025.
“As we plan for our entry into the US market, enhancing our communications and outreach to the investment community is crucial,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “Our partnership with B2i Digital allows us to connect with investors who see the potential in our unique approach to drug screening, particularly in industries where workplace safety is paramount.”
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company’s story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant investors to each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com.
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
https://b2idigital.com
212.579.4844 Office
david@b2idigital.com
https://www.linkedin.com/in/davidshapironyc
https://www.linkedin.com/company/b2i-digital
https://x.com/b2idigital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://www.pinterest.com/b2idigital/
https://www.tiktok.com/@b2idigital
https://www.threads.net/@b2i_digital
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Intelligent Bio Solutions Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Intelligent Bio Solutions Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
When will Intelligent Bio Solutions (INBS) enter the US market?
What is Intelligent Bio Solutions' (INBS) new drug screening technology?
Who has Intelligent Bio Solutions (INBS) partnered with for investor marketing?
